| Literature DB >> 24241535 |
Sérgio B Sousa1, Dagan Jenkins2, Estelle Chanudet3, Guergana Tasseva4, Miho Ishida5, Glenn Anderson6, James Docker7, Mina Ryten8, Joaquim Sa9, Jorge M Saraiva10, Angela Barnicoat11, Richard Scott11, Alistair Calder12, Duangrurdee Wattanasirichaigoon13, Krystyna Chrzanowska14, Martina Simandlová15, Lionel Van Maldergem16, Philip Stanier7, Philip L Beales17, Jean E Vance18, Gudrun E Moore5.
Abstract
Lenz-Majewski syndrome (LMS) is a syndrome of intellectual disability and multiple congenital anomalies that features generalized craniotubular hyperostosis. By using whole-exome sequencing and selecting variants consistent with the predicted dominant de novo etiology of LMS, we identified causative heterozygous missense mutations in PTDSS1, which encodes phosphatidylserine synthase 1 (PSS1). PSS1 is one of two enzymes involved in the production of phosphatidylserine. Phosphatidylserine synthesis was increased in intact fibroblasts from affected individuals, and end-product inhibition of PSS1 by phosphatidylserine was markedly reduced. Therefore, these mutations cause a gain-of-function effect associated with regulatory dysfunction of PSS1. We have identified LMS as the first human disease, to our knowledge, caused by disrupted phosphatidylserine metabolism. Our results point to an unexplored link between phosphatidylserine synthesis and bone metabolism.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24241535 DOI: 10.1038/ng.2829
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330